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INTRODUCTION 
1. Cancer and genetic instability 
Cellular responses to DNA damages have a critical role in tumor genesis. 
These response mechanisms comprise the processes of DNA damage 
sensation, cell-cycle arrest, DNA-repair and apoptosis. Inherited or acquired 
alterations in “care taker” genes, which are involved in the maintenance of 
genomic integrity, may lead to uncontrolled cell proliferation and 
accumulation of genetic errors. 
1.1 Mismatch repair, genetic instability and chemoresistance 
The mismatch repair (MMR) system recognizes and repairs misincorporated 
bases, as well as small insertion or deletion loops arising during DNA 
replication. MMR components have also been implicated in cell-cycle 
regulation and the p53-dependent apoptotic response to a variety of DNA 
damage. These functions on the one hand promote genetic stability, on the 
other hand are relevant to the chemotherapeutic sensitivity. In human cells, 
mismatch recognition is performed by hMSH2 heterodimerized either with 
hMSH6 for base-base mismatches and loops of one or a few nucleotides or 
with hMSH3 for insertion/deletion of two or more extrahelical bases. These 
complexes then interact with another heterodimeric complex, composed of 
hMLH1 and hPMS2. 
1.1.1. Mismatch repair defects in colorectal carcinoma 
Germline alterations of the MMR genes result in autosomal dominantly 
inherited predisposition to hereditary nonpolyposis colon carcinoma 
(HNPCC). This syndrome is characterized by early onset colorectal 
carcinoma and extracolonic epithelial-derived tumors most often located in 
the gastrointestinal and the urogenital tracts. In the majority of the HNPCC 
cases, germline mutations of the hMLH1 and/or hMSH2 genes can be 
demonstrated. The hallmark of mismatch repair deficiency is microsatellite 
instability (MSI) that is alteration in length of short repetitive sequences of 
the genome by small deletions or insertions. Amsterdam criteria (I and II) 
and Bethesda guidelines serve as bases for patient selection. Silencing of 
hMLH1 gene by promoter methylation occurs mainly in sporadic tumors and 
this is the principal mechanism of MMR inactivation in sporadic colorectal 
cancers with high microsatellite instability. Losses or defects of MMR 
factors can confer resistance to cisplatin. This resistance could either be 
explained by secondary mutations in effectors of apoptosis due to genetic 
instability, or by the failure of MMR in linking the detection of damage to 
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apoptosis. In addition to the platinum derivatives, loss of function of the 
MMR is associated with resistance to antracyclines and fluoropirimidines.  
1.1.2. Chemosensitivity of testicular germ cell tumors and the MMR 
The majority of testicular germ cell tumors (TGCTs) are highly sensitive to 
cisplatin-based chemotherapy, but a small fraction of cases are resistant to 
the effects of chemotherapy. The exquisite chemosensitivity of GCTs seems 
to be the consequence of several factors, including the lack of drug export 
and detoxification mechanisms, low DNA-repair capacity, sensitive DNA-
damage detection systems with initiation and execution of apoptotic 
pathways. For the development of a resistant phenotype no uniform 
explanation can be offered. A recent study suggested that failure to initiate 
apoptosis due to defects in MMR might contribute to resistance. 
1.2. p53 - the guardian of the genomic integrity 
The tumor suppressor protein p53 plays a critical role in the cellular response 
to DNA damage by regulating genes involved in cell cycle progression, 
apoptosis and genomic stability. More than half of all human cancers lose the 
p53 function by mutation. Inactivation of the p53 pathway may lead to the 
selection of more aggressive tumors with a high degree of genetic instability, 
which can be associated with poor prognosis. As diverse drugs can kill tumor 
cells by activating common apoptotic pathways, mutations that disable p53-
dependent apoptosis can produce multidrug resistance. The majority of 
tumor-derived mutations are missense mutations mapped to the central DNA 
binding domain. 
Missense mutations in p53 may result also in dominant negative and 
oncogenic effects. The dominant negative effect corresponds to the capacity 
of the mutant protein to complex with the product of the wild-type allele to 
inactivate its function. P53 mutants can form hetero-tetramers with other 
members of the p53 family (p63 and p73) leading to inactivation their ability 
to induce apoptosis. The binding affinity of mutant p53 to p73 is influenced 
by a common p53 polymorphism at residue 72. p53 mutants with R72 allele 
proved to be more potent inhibitors of chemotherapy-induced apoptosis than 
those of P72 variants. The oncogenic effects of mutant p53 may partly be 
related to that p53 mutants seem to transactivate or repress specific genes 
(MDR1, c-myc, PCNA, EGFR). 
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AIMS OF THE THESIS 
In this study we examined such genetic events which set a permissive 
background for the selection of malignant tumor cells, and also have an 
effect on therapeutic sensitivity. The mismatch repair system and the p53 
protein as representatives of “care takers” are involved in the maintenance of 
the genomic integrity. We set the aim to examine the effects of the main 
mismatch repair genes (hMLH1 and hMSH2) in the predisposition to 
hereditary colorectal cancer, and the influence of these genes on the 
therapeutic sensitivity of testicular germ-cell tumors. We investigated 
mutations of the p53 gene in primary head and neck tumors with the view to 
outline their prognostic values in the clinical outcome and the therapeutic 
responsiveness.  
The following issues were set for investigation: 
A) Mismatch repair genes and proteins in hereditary nonpolyposis 
colorectal carcinomas (HNPCCs) and testicular germ cell tumors 
(TGCTs) 
1. The germline mutational spectrum of Hungarian HNPCC families. 
1.1. Establishment of the most appropriate method to screen HNPCC 
suspected patients. 
1.2. Definition of germline mutations and polymorphisms in hMLH1 and 
hMSH2 genes of the selected patients and evaluation of their impact on 
disease development following pedigree analysis. 
2. Evaluation of mismatch repair deficiency, microsatellite instability and 
hMLH1 methylation as predictive markers in chemotherapeutic 
sensitivity of TGCTs. 
B) Investigation of the p53 gene in head and neck tumors 
1. Analysis of prognostic value of p53 mutations in primary head and neck 
squamous cell carcinomas (HNSCCs) and normal appearing resection 
margins. 
2. The role of p53 R72P polymorphism in the clinical outcome of HNSCC 
patients. 
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The analysis of resection margins has revealed that almost the one third of 
the normal appearing samples harbor the mutation of the primary tumor. 
Mutational analysis of surgical margins may therefore be of value in the 
prediction of local recurrence and in the decision making process for 
postoperative therapy. 
Analyzing the R72P polymorphism of p53 gene in HNSCC patients we 
concluded that the codon 72 genotype alone has no predictive value for 
clinical outcome, but allelotyping of the mutant allele may be useful to 
predict therapeutic sensitivity. 
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MATERIALS AND METHODS 
1. Examination of mismatch repair in HNPCC and TGCT patients 
1.1. Patients 
1.1.1. HNPCC suspected patients: 36 patients, operated at the 1st 
Department of Surgery, University of Debrecen, Medical and Health 
Sciences Center between 2003 and 2005, were selected on the basis of 
Bethesda Guidelines. Two index patients with very early tumor 
manifestation and their cooperative family members were involved in 
pedigree analysis. 
1.1.2. TGCT patients: Specimens of 51 patients with TGCT were collected 
between 1993 and 2003 at the National Institute of Oncology, Budapest. 
Prior to surgery patients received neither radio- nor chemotherapy. The 
tumors were histopathologically classified according to the WHO criteria. 
Staging was based on UICC classification. Early stage was defined as stage I 
or stage II/A. Late stage was defined as stage II/B, II/C or stage III. Patients 
were considered refractory when progression or relapse occurred despite of 
adequate initial or salvage treatment. Patients with a complete remission and 
relapse-free follow-up of more than one year were considered as 
chemosensitive. 
1.2. Immunohistochemistry 
Paraffin embedded tissue sections of HNPCC and TGCT samples were 
deparrafinized. Following heat induced epitope retrieval immuno-
histochemistry was performed using mouse anti hMLH1 (G168-728, Cell 
Marque, Hotsprings, USA; G168-15, BD Biosciences Pharmingen, USA), 
anti hMSH2 (G219-1129, Cell Marque, Hotsprings, USA; 25D12, 
Novocastra, UK) and anti hMSH6 (GTBP.P1/66.H6, Serotec, UK) 
antibodies. Biotin-streptavidine detection kit (LSAB, Dako, Glostrup, 
Denmark) with VIP chromogen (Vector, Burlingame, USA) and EnVision+ 
System (Dako Cytomation, CA, USA) with DAB substrate-chromogen were 
used for visualization. 
1.3. DNA isolation 
1.3.1. DNA isolation from paraffin embedded tissue samples of HNPCC 
and TGCT patients: Paraffin-embedded cancerous tissue samples of the 
patients were deparaffinized and DNA was extracted by the use of High Pure 
PCR Template Purification Kit (Roche Diagnostics, Mannheim, Germany). 
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1.3.2. DNA isolation from whole blood of the HNPCC patients and their 
relatives: DNA was extracted with the use of QIAamp DNA Blood Midi kit 
(Qiagen, Hilden, Germany). 
1.4. Microsatellite instability analysis 
Microsatellite instability test was performed on tumor samples and 
corresponding normal or blood samples from HNPCC suspected patients and 
TGCT patients. Two mononucleotide repeat markers (BAT25 and BAT26) 
and three dinucleotide repeat markers (D2S123, D5S346, D17S250) were 
studied according to the international reference panel recommendations, 
fluorescence labeled PCR fragments were separated and analyzed by ABI-
310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) 
 
1.5. Mutation detection in HNPCC patients 
1.5.1. PCR, heteroduplex (HD) and single strand conformation 
polymorphism (SSCP) analyses: DNA samples of patients with high level 
MSI were used to amplify all exons of the hMLH1 and hMSH2 genes. SSCP 
and HD analysis of PCR products were performed by electrophoresis in 
MDE gel (Cambrex Bio Science Rockland, Rockland, ME, USA) and 
visualized by silver staining. 
1.5.2. Sequencing analysis: Sequencing was performed in both directions 
with purified PCR products using BigDye terminator cycle sequencing kit 
v.3.1 and the reaction products were run in ABI-PRISM 310 Genetic 
Analyzer (Applied Biosystems, Foster City, CA, USA). 
1.5.3. Detection of large deletions: Genomic deletions were tested by the use 
of SALSA MLPA Kit P003 MLH/MSH2 (MRC-Holland, Amsterdam, 
Netherlands) according to the manufacturer’s instructions. The amplification 
products were analyzed by capillary gel electrophoresis (ABI-3130). 
1.6. Promoter methylation analysis of hMLH1 gene in TGCT patients 
Sodium bisulfite conversion of the DNA template was performed. The 
bisulfite reaction converts the methylation information into sequence 
differences. The analysis was performed by the fluorescence-based real-time 
PCR assay, MethyLight. The PCR reactions were performed in 7900-HT 
SDS (Applied Biosystems, Foster City, CA, USA). Primer and probe sets 
designed for bisulfite-converted DNA were used: one set for the hMLH1 
promoter and a reference set for a CpG-free region of the β-actin (ACTB). 
SssI methylase (New England Biolabs, Ipswich, MA, USA) treated DNA 
was used as positive control. 
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These findings demonstrated that causative mutations coupled with single 
nucleotide polymorphisms have worse prognostic values and suggest close 
follow-up of carriers from their mid-twenties. 
 
2. Influence of mismatch repair on chemoresistance of testicular germ-
cell tumors 
It was shown earlier that cells defective in MMR are relatively resistant to 
fluoropirimidines and platinum derivatives. The majority of testicular germ 
cell tumors (TGCTs) are highly sensitive to cisplatin-based chemotherapy, 
but a small fraction of cases are resistant to the effects of chemotherapy. 
Although we found a strong correlation between weak or loss of hMLH1 
expression and promoter hypermethylation, MSI did not correlate with either 
of them. Similar to several sporadic cancer cases the genetic background for 
MSI is unclear. Expression of the MMR proteins, hMLH1 methylation and 
MSI did not show correlation with the clinico-pathological parameters and 
the therapeutic response. According to our findings reduced expression of 
MMR proteins and MSI have not proved to be predictive markers for 
chemotherapeutic resistance of TGCTs. 
 
3. Analysis of p53 mutations in head and neck squamous cell 
carcinoma (HNSCC) 
The majority of the alterations we found in the core domain encoding region 
were missense mutations. Most of the point mutations were C:G>T:A 
transitions. Five out of six C:G>T:A transitions at CpG sites were found in 
codons of the DNA-binding surface. We can suppose that CpG site 
mutations affecting the DNA-binding surface have some selection advantage 
against those affecting the β-structure. We have not found a significant 
correlation between the presence of mutation and the tumor stages, 
suggesting that p53 mutations occur at a relatively early stage. A significant 
trend observed between the tumor stage progression and the frequency of 
missense mutations on the DNA-binding surface supports the assumption 
that these mutations are responsible for a more aggressive phenotype. 
Patients with other than missense mutations (nonsense, splice mutations, 
deletions) showed significantly longer survival than patients with missense 
mutations. Moreover, the carriers of nonsense mutations were observed to 
survive for the longest periods. Our results suggest the idea of dual character 
of the p53 gene in which missense mutations render an oncogenic property to 
the protein, while other types of mutations disrupt its tumor suppressor 
functions. We suppose that oncogenic (gain of function) properties provide a 
selection advantage to missense mutants. 
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than patients with missense mutations. All but one of the four patients with 
nonsense mutation were still alive 84, 88 and 96 months after the surgery. A 
significant linear trend was seen between tumor stage progression and 
proportion of subjects with mutations affecting the DNA-binding surface 
(p=0.022).  
Twenty-two normal appearing resection margin samples of patients with p53 
core domain mutation were also analyzed. Six (27.27%) of these samples 
also carried the mutation identified in the corresponding tumor samples. 
3.2. SNP analysis of codon 72 of p53 gene: There were 48 R72R 
(53.9%), 39 R72P (43.8%) and 2P72P (2.3%) genotypes within the patient 
group. There were no significant differences in genotype (p=0.622) and 
allele distributions (p=0.683) between the patients’ group and the control 
group of healthy individuals. There were no significant correlation between 
the allele distribution and the tumor stages. The overall survival curves of the 
R/R and R/P genotypes were not significantly different (p=0.1490). 
 
DISCUSSION 
1. Evaluation of genetic alterations in HNPCC suspected patients 
Germline alterations of the MMR genes result in autosomal dominantly 
inherited predisposition to hereditary nonpolyposis colon carcinoma 
(HNPCC). Although HNPCC families not complying with the Amsterdam 
criteria show extremely low frequency of MMR gene mutations, several 
HNPCC patients can be missed by the obligate application of Amsterdam I 
and II criteria. Bethesda guidelines are applicable to select patients not 
fulfilling Amsterdam criteria in order to test MSI. Immunohistochemistry 
alone is not sufficient to use for prescreening because of its lower sensitivity, 
but it can be used to confirm MMR inactivation and to predict the gene being 
inactivated. 
Among the mutation carriers two patients had very early tumor 
manifestation. Two germline mutations were found in each of them. A 
nonsense mutation and a splice mutation proved to be pathogenic 
respectively. The missense mutations accompanying the former alterations 
did not cause pathogenicity when occurred alone in family members. The 
presence of these polymorphisms together with the pathogenic mutations 
causes an early onset of tumor at the age of the twenties and early thirties of 
the patients, whereas relatives harboring the single pathogenic mutation 
developed cancer in their forties and fifties, or have not had disease yet. 
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1.7. Statistical analysis 
Dichotomized variables gained from TGCT samples were tested by two-
sided Fisher’s exact test. Survival analysis was performed by using Kaplan-
Meier log-rank test. Differences were considered significant at p≤0.05 
significance level. The statistical tests were performed by SPSS 11.0 for 
Windows software (SPSS, IL, USA). 
2. Analysis of p53 mutations in HNSCC patients 
2.1. Patients 
89 primary HNSCC and corresponding normal samples of the oral cavity 
(34), the oropharynx (15), the hypopharynx (23) and the larynx (17) were 
obtained from patients operated at the Head and Neck Surgery Department of 
the National Institute of Oncology, Budapest, between 1997 and 1999. Prior 
to surgery patients did not receive chemo- or radiotherapy. UICC stages and 
grades of tumors were defined. All tissue samples were snap-frozen in liquid 
nitrogen and stored at –75 0C. 
2.2. DNA isolation 
DNA was isolated from the patients’ samples with the standard phenol-
chloroform extraction and ethanol precipitation following proteinase K 
digestion. 
2.3. p53 mutation detection 
PCRs covering the exons 5-6, exon 7 and exons 8-9 of p53 gene were 
performed. SSCP analysis and sequencing were performed according to the 
methods in 1.5.1. and 1.5.2. 
2.4. Single Nucleotide Polymorphism (SNP) analysis 
The codon 72 polymorphism of p53 gene was examined in paired tumor and 
normal samples of 89 HNSCC patients. PCR amplifications and melting 
curve analyses were performed by LightCycler instrument and software 
(v.3.5) (Roche Diagnostics, Mannheim, Germany). 
2.9. Statistical analyses 
Categorical data of two and more than two groups were compared by 
Fisher’s exact test and χ2 test respectively. Survival data of different 
populations were analyzed by Kaplan-Meier log-rank test. The above 
statistical tests were performed by GraphPad Instat 3 and GraphPad Prism 4 
softwares. The results were considered statistically significant at p≤ 0.05 
significance level. 
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RESULTS 
1. Screening of hereditary nonpolyposis colorectal cancer (HNPCC) 
patients 
1.1. Microsatellite analysis: Among the 36 patients, selected on the basis of 
the clinical symptoms and family history, 7 (19.4%) showed high 
microsatellite instability in their tumors. 
1.2. Mutation detection and sequencing: We have identified germline 
mutations in 5 of the 7 MSI-H patients. Altogether we have found three 
missense, two nonsense mutations, one splice mutation and a large deletion. 
Two germline point mutations were found in patient 1 and patient 2. In 
patient 1 p.E422X nonsense mutation was accompanied by p.N127S 
missense mutation in hMSH2. c.2210+1G>C splice site mutation in hMSH2 
and V716M missense mutation of hMLH1 were found in patient 2. 
1.3. Immunohistochemistry: Patients having the above-mentioned mutations 
showed the following alterations. Cancerous tissue of patient 1 did not 
express hMSH2. Tumor samples of patient 2 showed loss of both hMSH2 
and hMLH1 expressions. 
1.4. Pedigree analysis: In family 1 (family of patient 1) 7 persons carry the 
nonsense (E422X) mutations on the mother’s side. Each cancerous family 
member bears this mutation. The missense mutation (N127S) is present in 
both lineages, altogether in seven persons. All family members carrying only 
this missense mutation are healthy. Those patients who carry the nonsense 
mutation only were 43 and 56 years old when colon tumors were diagnosed. 
In cancer patients who have both mutations tumors were manifested at the 
age of 32 and 34. In family 2 (family of patient 2) 5 members have the splice 
mutation in hMSH2 (c.2210+1G>C). The missense mutation in hMLH1 
(V716M) occurs in 9 persons; two family members are homozygous for this 
mutation. The index patient and his brother carry both alterations. 
Synchronous tumors were diagnosed in the index patient at the age of 25, 
and adenoma was found in his brother at the age of 28. Their father carrying 
the splice mutation only was diagnosed with cancer at the age of 52. 
 
2. Investigation of the mismatch repair system in testicular germ-cell 
tumors 
2.1. Immunohistochemistry: Loss or weak staining of any MMR 
proteins was detected in 14 cases (27.5%). Four of them belonged to the 
chemoresistant group. Pathological hMLH1 expression was seen in 10 cases 
(19.6%). In one case all of the examined MMR proteins were lost. In 4 cases 
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hMHSH6 protein expression was lost. Three cases with loss of hMSH6 also 
showed loss of hMSH2 expression. No association was found with the 
therapeutic response. 
2.2. Microsatellite analysis: MSI was found at one microsatellite locus in 16 
cases (31.4%), however no sample showed high MSI. The proportion of MSI 
in the refractory group and in the sensitive group was 27.8% and 32.4% 
respectively. The MSI status did not correlate with any of the clinico-
pathological parameters, the therapeutic response and not either with MMR 
expression. 
2.3. Methylation analysis: We found hMLH1 hypermethylation in 11 cases 
(21.6%), of which 3 expressed hMLH1 protein strongly. However, 2 cases 
with loss of hMLH1 protein expression showed no hypermethylation. 
hMLH1 methylation was highly correlated with loss of nuclear hMLH1 
expression (p<0.0001) and with immunohistochemically-detected MMR 
deficiency (p=0.0005). In addition, hMLH1 methylation was not detected in 
any but 1 case in the refractory group. Four deaths occurred in this series, all 
of them belonging to the hMLH1 nonmethylated group. However the 
survival curves of the hMLH1 methylated vs. nonmethylated groups did not 
differ significantly (p=0.24). The hMLH1 methylation status did not show 
significant correlation with tumor stage, histology (seminoma vs. non-
seminoma) and microsatellite instability. 
 
3. Analysis of p53 mutations in head and neck squamous cell 
carcinoma (HNSCC) 
3.1. Mutation analysis: We found 37 mutations in exons 5-8 of p53 
gene, which affected 34 (38.2%) of the 89 patients examined. There were 
three patients who all had two mutations in this region. The most frequent 
changes at DNA level were C:G>T:A and A:T>G:C transitions (57.89%). 
The C:G>T:A transition was more than twice as frequent event as the 
A:T>G:C transition (39.47% vs. 18.42%). There were 25 missense (67.6%), 
4 nonsense (10.8%), 1 synonym (0.02%), 2 splice site (5.4%) mutations, and 
4 deletions (10.8%). Neither the overall nor the 5 year survival of patients 
with core domain mutations differed significantly from those without these 
mutations (p=0.63, p=0.44). Missense mutations were significantly more 
frequent on the DNA-contacting surface while other types of mutations 
occurred more often in the β-sandwich scaffold (p=0.03). Patients with 
mutations only on the DNA-binding surface showed worse survival than 
those with mutations only in the β-sandwich scaffold (p=0.04). Patients with 
other than missense mutations (nonsense, splice mutations, deletions) 
showed significantly longer overall (p=0.012) and 5 year survival (p=0.020) 
